DALLAS — The world’s first Western Hemisphere drug could lead to the world leading the way in treating cancer patients, a new study suggests.
In the journal Nature Medicine, researchers led by researchers from the University of California, Los Angeles and Harvard Medical School report on the discovery of a novel immunotherapy drug, “Biopropil” that could help stem the spread of melanoma.
The study was funded by the National Institutes of Health.
Scientists said they found the compound in a medicinal plant in South America.
They reported the discovery Wednesday in Nature Medicine.
The compound is a novel drug targeting melanoma cells.
It has been previously shown to slow tumor growth and kill cancer cells, but until now it had never been isolated from a plant.
“Our discovery of Biopropol in a plant has the potential to lead to a more effective and more cost-effective treatment than currently available drugs,” said Dr. Andrew Meech, a member of the UC-LA’s Department of Molecular Biology and Biotechnology and an author of the study.
The drug, which has already been approved by the U.S. Food and Drug Administration, is an inhibitor of a protein called tyrosine kinase.
Tyrosine is the building block for the proteins that control the production of a chemical messenger called tumor necrosis factor-alpha.
The drug blocks tyrosines from being absorbed into the body.
“The drug is very good at blocking tyrosinase and inhibiting its activity in melanoma,” said Mee-Mann, a professor of molecular medicine at the UC Berkeley School of Medicine.
“We are hopeful that we can use the drug in other types of cancer, such as those that are more resistant to conventional chemotherapy.”
While there have been few successful drug candidates for the treatment of melanomas, Meechan said it’s clear that the treatment has some promising potential.
“These drugs are really good at inhibiting tyrosylation, which is the process that the tyrosamines carry out,” he said.
“So we can think about these drugs as basically trying to take away the tumor suppressor.
It could be a lot of different molecules.”
In the study, the UC LA team reported that the drug’s effects on melanoma were mild, with only mild side effects and no significant side effects.
The researchers also reported that patients taking the drug had less aggressive tumors in comparison to those not taking the medication.
“It was really very exciting to see how much of a response the drug has,” said study senior author Dr. Daniela P. Bialo, an associate professor of medicine at UC Berkeley.
“To us, this is a really exciting discovery because it gives us a way to potentially slow down the growth of melanocytes and tumors.”
The researchers said the drug could be used in the treatment or prevention of a variety of other cancers, including leukemia and neuroblastoma.
Biodefense, an anti-malarial drug approved by President Donald Trump in 2018, also uses tyrosase inhibitors.
Researchers said Bioprotil could be particularly useful for treating melanoma patients who suffer from other types, such.
as lung cancer.
The treatment can reduce the amount of tumor-causing material in the body, which can be especially important for those suffering from other cancers.
The study’s findings could lead drug companies to look for new ways to use the compound.
Bioprotill, which the researchers dubbed “BOP”, stands for “bio-operatively-oxidized peptide,” or BOPs.
BOP is produced by bacteria called E. coli.
It’s known to be one of the best drugs for combating infections in the human body.
It’s been around for decades.
The bacteria that make BOP, called Enterobacteriaceae, have been known to produce it for thousands of years.
However, the discovery has recently received attention from the drug industry.
Biodefence, the anti-cancer drug approved in 2018 by President Trump, uses BOP in its treatment.
Bio-Operative-Oxidized Porphyrins, or BOPS, are an alternative to the usual treatment for melanoma, known as chemotherapeutic agents, or CTAs.
Chemotherapy involves the use of a cancer drug to kill cancerous cells.CTAs are an extremely expensive, but powerful, treatment.
They’re used to treat cancerous tissue in people with certain genetic mutations, but not cancerous organs like the lungs, eyes, liver, stomach, kidneys or spleen.
In a way, CTAs are like a pill: they’re a drug, but they’re only an injection.
However the drug can have an extremely powerful effect on tumors, particularly in the lungs and liver.
The UC Berkeley researchers report that the compound they found in the plant was similar to a chemotherapies